Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. DTCA/I, consumer secondary audience
  4. 280 - Is including the names of Rx products on sales rep business cards and email signatures allowed ? Or are these considered APS or potentially DTC advertising . Thank you
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

280 - Is including the names of Rx products on sales rep business cards and email signatures allowed ? Or are these considered APS or potentially DTC advertising . Thank you

Scheduled Pinned Locked Moved DTCA/I, consumer secondary audience
1 Posts 1 Posters 372 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Jennifer CarrollJ Offline
    Jennifer CarrollJ Offline
    Jennifer Carroll
    wrote on last edited by
    #1

    It appears that there is a chance that these cards will fall into the hands of consumers. We must therefore consider consumer regulations. The name of the drug alone would not exceed consumer regulations (provided the drug is not a narcotic or a controlled drug as consumer promotion of such products is completely prohibited). However, inclusion of anything which would allude to the therapeutic use of the listed drug (e.g. a drug rep title such as "Neuroscience Specialty Mood Representative") would exceed consumer restrictions for prescription products and for products used for the treatment of a schedule A disease. It is advisable to limit distribution to HCPs if including anything beyond the company name/address, the drug rep name & contact info, and a generic title such as "Product Representative". Should distribution be limited to HCPs as they contained specific drug rep types, PAAB would review these as corporate pieces with product mention. All cards across the company's product offerings may be submitted as a single piece. For each product we'd ensure the implied therapeutic classification is accurate and on-label. Note that inclusion of product claims would require fair balance.

    1 Reply Last reply
    0
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups